India to Kenya: Clindamycin Export Trade Route

The India to Kenya Clindamycin corridor is one of India's established pharmaceutical export routes, with 137 shipments documented worth a combined $4.6M USD. The route is dominated by THE MADRAS PHARMACEUTICAL, which alone accounts for roughly 57% of all export value, reflecting the consolidated nature of India's clindamycin manufacturing sector.

Across 37 active suppliers, the average shipment value stands at $33.4K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 83% of all shipments, consistent with clindamycin's non-urgent bulk-order profile.

Shipment activity peaks during January–March, with an average transit time of 16 days port-to-port. The route has recorded an annual growth rate of 16.0%, placing it at rank #1 among India's top clindamycin export destinations globally.

On the import side, key buyers of Indian clindamycin in Kenya include SYNERMED PHARMACEUTICALS (KENYA)LTD, WESSEX PHARMACEUTICALS LIMITED,, ZAWADI HEALTHCARE LIMITED and 42 others. SYNERMED PHARMACEUTICALS (KENYA)LTD is the single largest importer with 5 shipments valued at $2.6M USD.

India's clindamycin exports to Kenya are driven primarily by a handful of large-scale manufacturers. THE MADRAS PHARMACEUTICAL with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 37 active exporters signals a competitive but concentrated market — buyers in Kenya benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — THE MADRAS PHARMACEUTICAL, ATOZ PHARMACEUTICALS PRIVATE LIMITED, SUNRISE REMEDIES PRIVATE LIMITED — together account for 87% of total trade value on this route. The average shipment value of $33.4K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as clindamycin 300 mg tablet b.no.ke 14 202 and clindamycin 300 mg tablet b.no.ke 14 201, suggesting that buyers in Kenya tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, SYNERMED PHARMACEUTICALS (KENYA)LTD is the largest importer with 5 shipments worth $2.6M USD — representing 58% of all clindamycin imports from India on this route. A total of 45 buyers are active on this corridor.